FDA Grants Emergency Use Authorization for OraQuick Ebola 2.0 Rapid Test, Detects Virus in Living Patients and Suspected Deaths
The U.S. FDA granted emergency use authorization for the OraQuick Ebola 2.0 rapid antigen test, developed in partnership with the Biomedical Advanced Research and Development Authority. The test can detect the virus in both living patients and people suspected to have died from the disease.
From the sources (8 posts)
@reutersCanada to temporarily bar entry for foreigners who have recently been to Congo, against UN advice
@nypostOver 900 people dead in Congo's Ebola outbreak
@cgtnafricaMore than 900 people have died in the #Ebola outbreak in the Democratic Republic of the Congo, the country's health ministry said on Monday, as health authorities continue efforts to contain the spread of the highly infectious disease. (📷:C
@ajenglishEbola is spreading faster than any previous outbreak in Democratic Republic of Congo (DRC), with 37 new deaths recorded over just 24 hours at the weekend.
@ajenewsBREAKING: Confirmed Ebola cases in the DR Congo rise to 2,423, including 967 deaths. Health authorities report 79 new cases in the eastern Ituri and North Kivu provinces. 🔴 More on
@ajenglishRT @AJENews: BREAKING: Confirmed Ebola cases in the DR Congo rise to 2,423, including 967 deaths. Health authorities report 79 new cases in…
@businessThe US FDA granted emergency use authorization for a rapid Ebola test that can detect the virus in both living patients and people suspected to have died from the disease
@orasureWe're proud to announce that the U.S. FDA has granted Emergency Use Authorization for our OraQuick™ Ebola 2.0 Rapid Antigen Test. Developed in partnership with BARDA. Read press release→